Resetting Balance, Restoring Health
At Equillium, we leverage deep understanding of immunology and its role in disease to pioneer new products for severe autoimmune and inflammatory disorders.
About Itolizumab
Itolizumab is being developed in multiple severe immuno-inflammatory diseases.
Clinical Trials
Clinical trials in acute Graft-Versus-Host Disease (aGVHD), asthma, and SLE / lupus nephritis are actively enrolling patients.
Featured News
FDA fast track designation for itolizumab demonstrates that targeting CD6 may address the high unmet therapeutic need for lupus nephritis patients.